Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2016-06-13 Proxy Solicitation & In…
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
INFORMATION STATEMENT
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'DEF 14C INFORMATION STATEMENT' and is filed pursuant to Section 14(c) of the Securities Exchange Act of 1934. It is an Information Statement notifying shareholders of an amendment to the Articles of Incorporation increasing authorized shares of common and preferred stock. The document explicitly states it is not a proxy solicitation and no meeting will be held. The content focuses on corporate governance changes related to capital structure authorization and shareholder notification. This type of filing corresponds to a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes or consents for corporate actions. The document is not an Annual Report, Earnings Release, or other financial report, nor is it a simple announcement or certification. Therefore, the correct classification is PSI with high confidence.
2016-06-13 English
PRELIMINARY INFORMATION STATEMENT
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed pursuant to Section 14c of the Securities Exchange Act of 1934. It is titled as an "Information Statement" and explicitly states it is not a proxy solicitation or a meeting notice. The content focuses on informing shareholders about an amendment to the Articles of Incorporation to increase authorized shares of common and preferred stock. It includes detailed background, reasons for the amendment, and the implications for shareholders. The document is not a full annual or quarterly report, nor is it an earnings release or a proxy solicitation. It is a formal communication to shareholders about corporate governance matters related to capital structure changes but does not request votes or proxies. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings or corporate actions. Although this document states no vote is being sought, Schedule 14C filings are classified under Proxy Solicitation & Information Statement filings as they provide information to shareholders about corporate actions. Therefore, the appropriate classification is PSI with high confidence.
2016-05-31 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2016
2016-05-09 English
PRIMARY DOCUMENT
Director's Dealing
2016-04-26 English
PRIMARY DOCUMENT
Director's Dealing
2016-04-25 English
PRIMARY DOCUMENT
Director's Dealing
2016-04-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.